Novel biomarkers like GDF15 and OPN show promise in diagnosing and prognosticating uterine sarcoma, potentially enabling early identification and tailored therapy. Blood-based markers such as NLR and ...
A new liquid biopsy test using artificial intelligence models could help spot a rare type of bone and soft tissue cancer that ...
Immunotherapy, particularly ICIs, shows potential in treating certain STS subtypes, but efficacy varies and requires further investigation. Blood-based biomarkers, including neutrophil-to-lymphocyte ...
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announces that the United States Food and ...
ADCE-D01 targets the uPARAP protein in sarcomas, delivering medication directly to cancer cells, showing promise in early studies. The ADCElerate1 trial evaluates ADCE-D01's safety, tolerability, ...
Immutep Limited (NASDAQ:IMMP) is a clinical-stage biotechnology company developing LAG-3–based immunotherapies for cancer and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Sarcoma is a rare and complex cancer that most people never ...
SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results